VivoSeq
Other

Obese

1

Pipeline Programs

6

Active Trials

14

Companies Involved

Obese is an early-stage landscape with 1 program across 14 companies. The most active players are Eli Lilly, Merck & Co., Rhythm Pharmaceuticals.

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

6/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Preclinical
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Trial Status

64

clinical trials

Completed50 · 78%
Unknown status4 · 6%
Recruiting3 · 5%
Withdrawn2 · 3%
Not yet recruiting2 · 3%
Terminated2 · 3%
Other1 · 2%

Trial Activity

64 trials

A Trial of HRS-5817 in Obese Participants
Recruiting·AAtridia Pty Ltd.·Phase 1·NCT07238647·40 enrolled
A Study to Assess S-309309 in Healthy and Obese Participants
Completed·Shionogi logoShionogi·Phase 1·NCT05247970·74 enrolled
A Study of LY3457263 in Obese Participants
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT05582096·38 enrolled
Pharmacokinetics of Ceftaroline in Normal and Obese Subjects
Completed··Phase 1·NCT01648127·32 enrolled
Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects
Completed··Phase 4·NCT01560143·12 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)